INVESTOR EVENT Shaping the Future of Cardiovascular Care: Innovative Technologies. Improved Outcomes.

Forward Looking Statements Forward Looking Statements Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “projects,” “believes,” “seeks,” “estimates,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics’ expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2024. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason. 2

AngioDynamics We are a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by focusing on cardiovascular disease and cancer. Our execution strategy is built on innovative R&D, clinical and regulatory pathway expansion, and customer centric sales performance. 523M diagnosed in 2020 ~19 million deaths2 19.3M diagnosed in 2020 ~10 million deaths5 Cardiovascular Disease Causes 1 in 3 Deaths Globally1 Cancer Causes 1 in 6 Deaths Globally3 3

AngioDynamics Summary AngioDynamics Summary 4

Venous Thromboembolism (VTE) $5.3B US TAM* AngioDynamics Cardiovascular Portfolio Differentiated technologies and a comprehensive portfolio enable us to be a strong competitor within high growth Cardiovascular Disease market Cardiovascular Disease Cancer MINI STICK MAX Prostate Care $780M US TAM* Peripheral Artery Disease (PAD) $760M US TAM* Med Tech Med Device * Management estimates & industry sources 5

AngioDynamics MedTech Revenue Contribution ~15% ~45% FY2021 $3.0B FY2023 $6.0B FY2025 $10.0B FY2018 $1.3B Total Addressable Markets Our demonstrated successful execution in portfolio optimization, clinical and regulatory expansion, and product introductions drives growth… Med TechGrowth Cardiovascular Growth 6

VENOUS ARTERIAL 7

Cardiovascular Arterial With over 100,000 patients treated,6 the Auryon Atherectomy System is projected in FY25 to exceed cumulative sales of $180M since its September 2020 launch 7 Served $500M M A R K E T D Y N A M I C S Auryon ~10%+ ABT 38% BSX 6% PHG 15% MDT 31% ANGO 10% Treat all levels of calcification8-10 Indicated for in-stent restenosis Treats above and below the knee (inc. below the ankle) Portable, 110V outlet, low noise, touch screen Debulk in fewer passes Designed for hospital and lab8-10,13 Protective of vessel wall10-12 Targeted biological reactions to address risk of perforations Built-in aspiration to address risk of embolization Ability to crack medial calcification21 Shock waves break severe calcification, including medial arterial calcification Contributes to plaque modification that may help improve vessel compliance 8

P E R I P H E R A L A R T E R Y D I S E A S E (PAD) Aspiration capability and indicated for ISR and to aspirate thrombus adjacent to stenosis Intuitive, Windows-based touch screen Small and portable (29 in x 13 in x 37 in) Lightweight (198.45 lbs.) 110 V power outlet No calibration and minimal warm up time Ability to treat ISR, CTO, Calcified, Fibrotic, Thrombus and Soft Plaque lesions, ATK and BTK Foot pedal for hands-free activation Auryon’s solid-state laser technology has three times more affinity for lesion material than vessel walls and is capable of treating all lesions types ATK, BTK8-10 & ISR** 355 nm wavelength 10-25 ns pulse width 9

Auryon Platform Technology The Auryon System is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium10,11,14 Wavelength (nm) The distance between 2 successive waves determines absorption rate and penetration depth Pulse width (ns) The duration of each pulse determines level of diffusion Amplitude (mJ/mm2) The height of the wave determines power10,11,13 Why wavelength matters:15-18 Each type of tissue interacts differently with a given wavelength7,8 Longer wavelengths are absorbed at shallower depths than shorter wavelengths, resulting in lower photon energies7,8,9,10 Importance of pulse width and amplitude15,17,19,20 Greater amplitude is achieved with shorter pulses, which can deposit energy before thermal diffusion occurs10 To localize the effects to the target tissue without thermal damage, the energy delivered needs to be faster than the time it takes for the heat to diffuse E F F I C I E N T Does not require calibration before each procedure May eliminate the need for multiple catheters for a single procedure Has the potential to debulk with minimal passes A D A P T A B L E Treats all infrainguinal lesions8,9,10 Treats infrainguinal lesions both above and below knee Has the ability to crack arterial calcium and prep the vessel21 S M A R T Performs targeted biological reaction to address the risk of perforations22-23 Nonreactive to contrast media allowing simultaneous ablation and observation of fluoroscopy images Includes built-in aspiration to address the risk of embolization* *2 and 2.35 mm catheters 10

Auryon Platform Technology The Auryon System’s dual method of action: Micro-CT Study21 Intimal Plaque/Calcium Debulking Works on removing different plaque morphologies, ATK – BTK and ISR Plaque/Calcium Modification Photomechanical shockwaves penetrate the medial wall to crack/modify plaque to bring pulsatility (elasticity/compliance) back to aging vessels. Intimal Arterial Calcification Medial Arterial Calcification Mechanism #1 Mechanism #2 MODIFY REMOVE CRACK calcium & REMOVE plaque with ONE technology This study was performed on cadavers, not on human subjects, and these results have not been validated in subsequent human research 11

Patient Enrollment Beginning Q2 CY 2025 RCT: 224 Patients Registry: ~1,500 Patients Initial European Experience in Coronary Artery Disease Auryon Platform Technology The Auryon System's technology has demonstrated safety and efficacy in PAD and presents an opportunity to expand into additional disease states MicroCT Pre-Clinical Study Published Dec. 2023 Established Secondary Mechanism of Action Auryon w/ Angioplasty vs. Angioplasty alone Below The Knee (BTK) PATHFINDER Registry 12 Mo Published May 2024 Auryon BTK Prospective Study Published May 2024 Promising Initial Study Results Safety, Efficacy & Versatility ~$900M US TAM* PMA Consideration P E R I P H E R A L A R T E R Y D I S E A S E (P A D) C O R O N A R Y A R T E R Y D I S E A S E (C A D) 12

VENOUS ARTERIAL The AngioVac Cannula is indicated for use as a venous drainage cannula and for removal of fresh, soft thrombi or emboli during extracorporeal bypass for up to 6 hours. The AlphaVac cannula is indicated for the non-surgical removal of thrombi or emboli and aspiration of contrast media and other fluids from the vasculature. It is intended for use in the venous system and for the treatment of Pulmonary Embolism

Cardiovascular Venous Venous Thromboembolism (VTE) represents an attractive, high growth, underpenetrated market opportunity TAM $6B PE $3B DVT $3B Right Heart $120M Deep Vein Thrombosis (DVT) Mechanical Thrombectomy is estimated to have penetrated ~15% of the TAM 22 Mechanical Thrombectomy is expected to grow ~20% in 202523 M A R K E T D Y N A M I C S Growth is driven by rising intravenous drug abuse, an aging population, and increased pacemaker prevalence More interventionalists embrace percutaneous techniques and the structural heart market is expanding Right Heart Pulmonary Embolism (PE) Mechanical Thrombectomy is estimated to have penetrated ~25% of the TAM 22 Mechanical Thrombectomy is expected to grow ~16% in 2025 23 14

The AngioVac System allows for the continuous aspiration of embolic material such as thrombi and emboli from the venous system while simultaneously reinfusing the patient’s own filtered blood to limit procedural blood loss. MULTIPLE TIP ANGLES 200, 850, 1800 Proprietary Funnel Design Allows for Significant Clot Removal Radiopaque Markers Better Tip Visibility Large-BORE Aspiration 42FR & 30FR Opening The AlphaVac System allows for the controlled aspiration of embolic material such as thrombi and emboli from the venous system. Thrombus Management All-purpose technology platforms targeted at peripheral and cardiovascular thrombolytic events, including small and large vessels 15

AngioVac Technology The only system that enables continuous aspiration and simultaneous reinfusion of blood, empowering physicians to treat more complex cases using minimally invasive techniques Aspiration & Simultaneous Reinfusion Proprietary Funnel On-circuit aspiration provides surgical results via percutaneous access by simultaneously reinfusing blood back in the patient’s body, minimizing blood loss. Funnel tip design enables efficient clot aspiration and compression 18Fr (33Fr) & 22Fr (42Fr) options More than 100 publications on the use of the AngioVac system24 Use of the device has been published for caval thrombi, cardiac masses and thrombi25 16

Actual procedure results, these images represent the experience of one institution and are not indicative of all procedural results. Clot Removal 30 min. *Dr. Keeling is a paid consultant of AngioDynamics EMORY HOSPITAL – MIDTOWNDr. Brent Keeling* (CT) 17

AlphaVac Technology Handle & Control Features MALE AND FEMALE CONNECTION Ensures correct connection SYRINGE BARREL VOLUME LIMITING SWITCH Intuitive location | Multiple glove sizes DURABLE LABELS Visible in low light environments VACUUM LOCK Controlled, single-hand design ANGLED HILT Easy access to vacuum lock TEXTURED GRIP Enhances grip control DIRECTIONAL LABELS Cannula | Waste Bag ANGLED EXIT Prevents large thrombus clog SPACER Allows sterile blood path and confirms plunger passes shelf-life constraints ROBUST DESIGN Enables smooth pulls with contemporary design 18

Advanced - Large Bore Aspiration CANNULA Proprietary FUNNEL Manual Aspiration HANDLE Complete SYSTEM IU HEALTHDr. Thomas Casciani (IR) & Dr. Sabah Butty* (IR) *Dr. Butty is a paid consultant of AngioDynamics Actual procedure results, these images represent the experience of one institution and are not indicative of all procedural results. 19 Only the AlphaVac F1885 System is indicated for the treatment of pulmonary embolism (PE) . The AlphaVac F2220 and F22180 Systems are not indicated for the treatment of PE.

Pulmonary Embolism Indication Study Approval March 2022 Enrolling October 2022 Enrollment Complete December 2023 Study Complete January 2024 CE Mark Approval May 2024 FDA Clearance AlphaVac F1885 for PE April 2024 Publication of APEX-AV Trial Results in JSCAI January 2025 20 Only the AlphaVac F1885 System is indicated for the treatment of pulmonary embolism (PE) . The AlphaVac F2220 and F22180 Systems are not indicated for the treatment of PE.

APEX – AV Pivotal Study 21 Number of Sites 25 US Sites Number of Patients 122 Timeline Oct. 2022 – Dec 2023 APEX (AlphaVac) FLARE (FlowTriever ) EXTRACT-PE28 (Indigo) Reduction in Clot Burden 35.5% 9.3% 11.3% AlphaVac F1885 received FDA clearance for PE following APEX-AV study demonstrating efficacy and significantly improved reduction in clot burden vs. competitive technologies Significant reduction in the RV/LV ratio26 Significant improvement in the RV function 0% mortality rate29 Significant reduction in clot burden26 Large funnel size (33 Fr) may aid in reducing the clot burden Procedure efficiency 37.2 min mean procedure time29 Atraumatic tip provides easy and efficient navigation in the Pas Ability to minimize blood loss30 21 Only the AlphaVac F1885 System is indicated for the treatment of pulmonary embolism (PE) . The AlphaVac F2220 and F22180 Systems are not indicated for the treatment of PE.

AngioDynamics Summary Our Med Tech segment operates in key markets with unique technologies that deliver proven clinical outcomes We have a strong track record in portfolio management, R&D, clinical and regulatory expansion, and customer-centric sales & marketing Our Med Device segment funds investments driving Med Tech growth We maintain a debt-free, strong balance sheet We expect to be Adj. EBITDA positive by FY2025 and cash flow positive by FY2026 Our company is positioned for sustainable revenue growth and profit for years to come 22

Shaping the Future of Cardiovascular Care: Innovative Technologies. Improved Outcomes. INVESTOR EVENT

References FULL RISK INFO: https://www.angiodynamics.com/about-us/risk-information Management estimates & industry sources https://pmc.ncbi.nlm.nih.gov/articles/PMC10809869/#:~:text=Cardiovascular%20diseases%20have%20remained%20the,recorded%20in%202021%20%5B1%5D. https://pmc.ncbi.nlm.nih.gov/articles/PMC10830426/#:~:text=In%202020%2C%20worldwide%2C%20an%20estimated,increase%20of%2018.7%25%20from%202010. https://www.who.int/news-room/fact-sheets/detail/cancer#:~:text=Cancer%20is%20a%20leading%20cause,and%20rectum%20and%20prostate%20cancers. https://pubmed.ncbi.nlm.nih.gov/33538338/#:~:text=Worldwide%2C%20an%20estimated%2019.3%20million,cancer%2C%20with%20an%20estimated%202.3 https://investors.angiodynamics.com/node/22881/html AngioDynamics’ J.P. Morgan Healthcare Conference Presentation https://investors.angiodynamics.com/static-files/f7e7b49f-744d-4169-9a66-95a78d2f1525. Published 2025 AngioDynamics’ Cardiovascular Investor Presentation https://investors.angiodynamics.com/. Published 2005 Rundback J, Chandra P, Brodmann M, Weinstock B, Sedillo G, Cawich I, et al. Novel laser-based catheter for peripheral atherectomy: 6-month results from the Eximo Medical B-Laser™ IDE study. Catheter Cardiovasc Interv. 2019;1-8. Shammas NW, Chandra P, Brodmann M, Weinstock B, Sedillo G, Cawich I, et al. Acute and 30-day safety and effectiveness evaluation of Eximo Medical’s B-Laser™, a novel atherectomy device, in subjects affected with infrainguinal peripheral arterial disease: Results of the EX-PAD-03 trial. Cardiovas Revasc Med. 2020;21(1):86-92. Auryon. Instructions for use. AngioDynamics; 2019. Herzog A, Bogdan S, Glikson M, Ishaaya AA, Love C. Selective tissue ablation using laser radiation at 355 nm in lead extraction by a hybrid catheter; a preliminary report. Lasers Surg Med. 2016;48(3):281-287. Herzog A, Steinberg I, Gaisenberg E, Nomberg R, Ishaaya AA. A route to laser angioplasty in the presence of fluoroscopy contrast media, using a nanosecond-pulsed 355-nm laser. IEEE J Sel Top Quantum Electron. 2016;22(3):342-347. Kuczmik W, Kruszyna L, Stanisic MG, Dzieciuchowicz L, Ziaja K, Zelawski W, et al. Laser atherectomy using the novel B-Laser™ catheter, for the treatment of femoropopliteal lesions: twelve-month results from the EX-PAD-01 study. Not yet published. Vogel A, Venugopalan V. Mechanisms of pulsed laser ablation of biological tissues. Chem Rev. 2003;103(2):577-644. Akkus NI, Abdulbaki A, Jimenez E, Tandon N. Atherectomy devices: technology update. Med Devices (Auckl). 2015;8:1-10. Rawlins J, Din JN, Talwar S, O’Kane P. Coronary intervention with the Excimer laser: review of the technology and outcome data. Interv Cardiol. 2016;11(1):27-32. Jacques SL. Role of tissue optics and pulse duration on tissue effects during high-power laser irradiation. Appl Opt. 1993;32(13):2447-2454. Beek JF, van der Meulen FW, Gijsbers GHM, Welch AJ, Hogervorst W, van Gemert MJC. Laser physics and laser-tissue interaction. Laser Surg Child. 1998;10-49. Taylor RS, Higginson LAJ, Leopold KE. Dependence of the XeCl laser cut rate of plaque on the degree of calcification, laser fluence, and optical pulse duration. Lasers Surg Med. 1990;10(5):414-419. Photonics Media. Shorter pulse widths improve micromachining. https://www.photonics.com/Articles/Shorter_Pulse_Widths_Improve_Micromachining/a54123. Published June 2013. Accessed March 20, 2020. Rundback et al. Treatment effect of medial arterial calcification in below-knee after Auryon laser atherectomy using micro-CT and histologic evaluation. Cardiovasc Revasc Med. 2023 Jun 28;S1553-8389(23)00674-7. Truist, Penumbra, Inc. September 12, 2021 Equity Research, Med Tech Cardiovascular, Multi Company Note – January 25, 2024 https://pubmed.ncbi.nlm.nih.gov/?term=AngioVac&sort=date Moriarty JM, Rueda V, Liao M, Kim GHJ, Rochon PJ, Zayed MA, Lasorda D, Golowa YS, Shavelle DM, Dexter DJ. Endovascular Removal of Thrombus and Right Heart Masses Using the AngioVac System: Results of 234 Patients from the Prospective, Multicenter Registry of AngioVac Procedures in Detail (RAPID). J Vasc Interv Radiol. 2021 Apr;32(4):549-557. Ranade M, Foster MT 3rd, Brady PS, Sokol SI, Butty S, Klein A, Maholic R, Safar A, Patel T, Zlotnick D, Gans D, Pollak J, Ferrera D, Stegman B, Basra S, Moriarty J, Keeling B. Novel Mechanical Aspiration Thrombectomy in Patients With Acute Pulmonary Embolism: Results From the Prospective APEX-AV Trial. J Soc Cardiovasc Angiogr Interv. 2024 Dec 27;4(1):102463. Tu T, Toma C, Tapson VF, Adams C, Jaber WA, Silver M, Khandhar S, Amin R, Weinberg M, Engelhardt T, Hunter M, Holmes D, Hoots G, Hamdalla H, Maholic RL, Lilly SM, Ouriel K, Rosenfield K; FLARE Investigators. A Prospective, Single-Arm, Multicenter Trial of Catheter-Directed Mechanical Thrombectomy for Intermediate-Risk Acute Pulmonary Embolism: The FLARE Study. JACC Cardiovasc Interv. 2019 May 13;12(9):859-869. Sista AK, Horowitz JM, Tapson VF, Rosenberg M, Elder MD, Schiro BJ, Dohad S, Amoroso NE, Dexter DJ, Loh CT, Leung DA, Bieneman BK, Perkowski PE, Chuang ML, Benenati JF; EXTRACT-PE Investigators. Indigo Aspiration System for Treatment of Pulmonary Embolism: Results of the EXTRACT-PE Trial. JACC Cardiovasc Interv. 2021 Feb 8;14(3):319-329. Data on file https://www.jscai.org/article/S2772-9303(24)02152-5/fulltext Spectranetics Corporation. CVX-300 Excimer Laser System: Operator’s Manual. Version 28. 2019:1-56. 24